Showing results (61-70 of 324) with videos related to
Sort By:
Pageof 33
Melanoma Research|October 1, 2010
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanomaJade Homsi, Agop Y Bedikian, Nicholas E Papadopoulos, et al.JAMA Network Open|July 30, 2020
Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With CancerRahul A Sheth, Ravi Murthy, David S Hong, et al.Oncoimmunology|January 27, 2017
Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccinationFenge Li, Caixia Chen, Tao Ju, et al.The American Journal of Dermatopathology|November 14, 2012
Differential expression of the G-protein-coupled formyl Peptide receptor in melanoma associates with aggressive phenotypeNitin Chakravarti, Vijay G R Peddareddigari, Carla L Warneke, et al.American Journal of Clinical Oncology|June 10, 2009
Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanomaNicholas E Papadopoulos, Agop Bedikian, Sigrid Ring, et al.Melanoma Research|September 23, 2010
Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapyWen-Jen Hwu, Robert D Knight, Madhavi Patnana, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 14, 2010
TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapyShujuan Liu, Tamara Etto, Tania Rodríguez-Cruz, et al.Journal of Immunotoxicology|June 24, 2008
Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survivalAgop Y Bedikian, Marcella M Johnson, Carla L Warneke, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 10, 2002
Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cellsCarlos E Marroquin, Jennifer A Westwood, Rejean Lapointe, et al.Oncotarget|April 19, 2014
Pathways and therapeutic targets in melanomaEmma Shtivelman, Michael Q A Davies, Patrick Hwu, et al.Pageof 33